Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator

Although oncolytic viruses have shown great promise as cancer therapeutics, results from a recent phase III clinical trial indicate that their potency may need further improvement for a clear clinical benefit. Here, we report a novel strategy to increase the bystander effect of virotherapy by arming...

Descripción completa

Detalles Bibliográficos
Autores principales: Loya, Shana Marie Williamson, Zhang, Xiaoliu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352111/
https://www.ncbi.nlm.nih.gov/pubmed/25567538
http://dx.doi.org/10.1038/gt.2014.113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352111/
https://www.ncbi.nlm.nih.gov/pubmed/25567538
http://dx.doi.org/10.1038/gt.2014.113

Ejemplares similares